AUTHOR=Zhang Jin , Fan Xiongxiong , Zhang Xiaoyu , Jiang Fengli , Wu Yiping , Yang Beibei , Li Xinghuan , Liu Dong 

TITLE=Efficacy and safety of tocilizumab and baricitinib among patients hospitalized for COVID-19: a systematic review and meta-analysis

JOURNAL=Frontiers in Pharmacology

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1293331

DOI=10.3389/fphar.2023.1293331

ISSN=1663-9812

ABSTRACT=<p><bold>Introduction:</bold> Tocilizumab and baricitinib are recommended treatment options for COVID-19 patients with hyperinflammatory response; however, there is a lack of systematic review directly evaluating their efficacy and safety.</p><p><bold>Objective:</bold> This review was conducted to evaluate the efficacy and safety of tocilizumab and baricitinib in the treatment of hospitalized patients with COVID-19.</p><p><bold>Methods:</bold> Relevant databases were searched for studies that compared the effect or safety of baricitinib or tocilizumab in hospitalized patients with COVID-19. The mortality was the main outcome. The hospital length of stay or adverse drug reactions were taken into consideration as secondary endpoints. The analyses were performed in Revman 5.3 or Stata 16.0. The protocol and analysis plan were pre-registered in PROSPERO, with the registration number CRD42023408219.</p><p><bold>Results:</bold> In total, 10 studies with 2,517 patients were included. The overall pooled data demonstrated that, there was no statistically significant difference in the 28-day mortality rate and the hospital length of stay between the tocilizumab and baricitinib (OR = 1.10, 95% CI = 0.80–1.51, <italic>p</italic> = 0.57; OR = −0.68, 95% CI = −2.24–0.87, <italic>p</italic> = 0.39). The adverse reactions including secondary infection rate, thrombotic and bleeding events, and acute liver injury of tocilizumab were significantly higher than that of baricitinib. (OR = 1.49, 95% CI = 1.18–1.88, <italic>p</italic> &lt; 0.001,OR = 1.52, 95% CI = 1.11–2.08, <italic>p</italic> = 0.009; OR = 1.52, 95% CI = 1.11–2.08, <italic>p</italic> = 0.009; OR = 2.24, 95% CI = 1.49–3.35, <italic>p</italic> &lt; 0.001).</p><p><bold>Conclusion:</bold> In patients hospitalized with COVID-19, no discernible difference in therapeutic efficacy was observed between tocilizumab and baricitinib; however, the group treated with baricitinib demonstrated a significantly lower incidence of adverse effects.</p>